trial

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

NCTId NCT03359785
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 31 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2020-12-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
31 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2018-01-10
Primary completion
2020-12-21
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Luvadaxistat

Sponsors

Neurocrine BiosciencesLead Sponsor
TakedaCollaborator

Sites

1 total
Gaithersburg, United States

Linked catalysts

1
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophr — primary completion2020-12-21

Facts & assertions

4 sourced
Enrollment
31
Phase
PHASE2
Primary Completion Date
2020-12-21
Status
COMPLETED
relationships
The graph out of here
drug
Luvadaxistat
drug
lead_sponsor
Neurocrine Biosciences
company
collaborator
Takeda
company
indication
Schizophrenia
indication
Schizophrenia
indication